miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGF β and Wnt signaling

Stephan Emmrich,¹ Mareike Rasche,¹ Jennifer Schöning,¹ Christina Reimer,¹ Sarva Keihani,¹ Aliaksandra Maroz,¹ Ying Xie,² Zhe Li,² Axel Schambach,^{3,4} Dirk Reinhardt,¹ and Jan-Henning Klusmann^{1,5}

¹Pediatric Hematology and Oncology, Hannover Medical School, Hannover 30625, Germany; ²Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA; ³Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany; ⁴Division of Hematology/Oncology, Children's Hospital Boston, Boston, Massachusetts 02115, USA

Although regulation of stem cell homeostasis by microRNAs (miRNAs) is well studied, it is unclear how individual miRNAs genomically encoded within an organized polycistron can interact to induce an integrated phenotype. *miR-99a/100*, *let-7*, and *miR-125b* paralogs are encoded in two tricistrons on human chromosomes 11 and 21. They are highly expressed in hematopoietic stem cells (HSCs) and acute megakaryoblastic leukemia (AMKL), an aggressive form of leukemia with poor prognosis. Here, we show that *miR-99a/100~125b* tricistrons are transcribed as a polycistronic message transactivated by the homeobox transcription factor *HOXA10*. Integrative analysis of global gene expression profiling, miRNA target prediction, and pathway architecture revealed that *miR-99a/100*, *let-7*, and *miR-125b* functionally converge at the combinatorial block of the transforming growth factor β (TGF β) pathway by targeting four receptor subunits and two SMAD signaling transducers. In addition, down-regulation of tumor suppressor genes *adenomatous polyposis coli* (*APC*)/*APC2* stabilizes active β -catenin and enhances Wnt signaling. By switching the balance between Wnt and TGF β signaling, the concerted action of these tricistronic miRNAs promoted sustained expansion of murine and human HSCs in vitro or in vivo while favoring megakaryocytic differentiation. Hence, our study explains the high phylogenetic conservation of the *miR-99a/100~125b* tricistrons controlling stem cell homeostasis, the deregulation of which contributes to the development of AMKL.

[Keywords: AMKL; TGF β ; Wnt; hematopoiesis; *let-7*; *miR-125*]

Supplemental material is available for this article.

Received October 28, 2013; revised version accepted March 19, 2014.

Self-renewal, quiescence, proliferation, and differentiation are tightly controlled during normal hematopoiesis to ensure lifelong hematopoietic stem cell (HSC) homeostasis and blood production. Deregulation of these processes results in hematologic dysplasia, deficiency, myeloproliferation, or leukemia. Therefore, a complex interplay of cytokines and signaling cascades, including their downstream transcriptional effectors, controls the balance between self-renewal and proliferation on the one hand and quiescence and differentiation on the other hand. The transforming growth factor β (TGF β) and Wnt signaling pathways are major examples for two such opposing players.

Recently, microRNAs (miRNAs) have emerged as important regulators of hematopoiesis, which can fine-tune the activity of canonical signaling cascades. We and others have defined a central function of *miR-125b* in stem cell homeostasis and leukemogenesis (Klusmann et al. 2010b; O'Connell et al. 2010). In particular, we identified chromosome 21 (hsa21)-encoded *miR-125b-2* to be highly up-regulated in acute megakaryoblastic leukemia (AMKL), especially in Down syndrome (DS) patients. AMKL blasts were sensitive to depletion of this

⁵Corresponding author
E-mail klusmann.jan-henning@mh-hannover.de
Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.233791.113>.

© 2014 Emmrich et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

miRNA (Klusmann et al. 2010b). However, *miR-125b-2* is encoded within a phylogenetically highly conserved tricistron of miRNA genes on chromosome 21 that also contains *miR-99a* and *let-7c* (hsa21; *miR-99a/let-7c/miR-125b-2*) (Fig. 1A). A highly similar homolog of this tricistron can be found in identical configuration on hsa11 (*miR-100/let-7a-2/miR-125b-1*). Another less conserved homolog resides on hsa19 (*miR-99b/let-7e/miR-125a*).

A significant number of miRNA genes are located closely adjacent to each other in miRNA polycistrons.

The NCBI/hg18 human genome assembly features 1873 miRNA gene sequences, of which 42% are organized into polycistrons of two or more genes (Altuvia et al. 2005). Increasing evidence suggests that clustered miRNAs act together, achieving a regulatory net outcome on the cell (Chan et al. 2012). Accordingly, only the concerted action of two miRNA families within the *miR-302/367* cluster enabled miRNA-mediated reprogramming of somatic cells to induced pluripotent stem cells (Anokye-Danso et al. 2011). The *miR-17~92* cluster contributes to Myc-driven oncogenesis by

forming a positive feedback loop (He et al. 2005). Dissecting the *miR-17~92* clusters revealed *miR-19* as the crucial and dominant component of this effect (Mu et al. 2009).

Studies investigating the individual miRNAs of the *miR-99/100~125* tricistrons demonstrated conflicting functions. While *let-7c* was shown to stimulate granulocytic differentiation in AML cell lines and primary blasts, *miR-100* inhibited it (Zheng et al. 2012; Pelosi et al. 2013). Also, in other cellular contexts, *let-7* acts as a tumor suppressor, negatively regulating oncogenes such as *MYC*, *RAS*, and *HMGA2* (Johnson et al. 2005; Lee and Dutta 2007). However, the high phylogenetic conservation as well as the genomic redundancy of the *miR-99/100~125* tricistrons implicate a common regulatory function of the three miRNAs.

Here, we deciphered the functional linkage of *miR-99a/100*, *let-7*, and *miR-125b* and demonstrate how polycistronic miRNAs cooperate to create a common phenotype. We show that the miRNAs are produced from a single primary transcript as a polycistronic message that is induced by the stem cell transcription factor *HOXA10*. The tricistron miRNAs form an interaction network in which the combined activity of all three miRNAs converged to block the TGF β pathway and amplify Wnt signaling. A shift in the balance between these central pathways favors megakaryopoiesis and promotes expansion of HSCs. In AMKL, up-regulation of *miR-99a/100~125b* represents a strategy to escape TGF β -induced apoptosis and cell cycle arrest.

Results

miR-99a/100~125b miRNAs are expressed together as polycistronic message in normal and leukemic hematopoietic cells

To test whether the miRNAs residing in the *miR-99a/100~125b* tricistrons on hsa11 (*miR-100*, *let-7a*, and *miR-125b-1*) and hsa21 (*miR-99a*, *let-7c*, and *miR-125b-2*) are expressed as a polycistronic message (Fig. 1A), we quantified the expression of mature miRNAs and primary miRNAs in leukemic cell lines and primary cells. Hierarchical clustering indicated higher expression of all mature *miR-99~125* miRNAs in primary AMKL blasts and cell lines as compared with primary blasts or cell lines of other AML subtypes (Fig. 1B; Supplemental Fig. S1A). During normal hematopoiesis, *miR-99a~125b-2* (hsa21) and *miR-100~125b-1* (hsa11) miRNAs are primarily expressed together in CD34⁺ hematopoietic stem and progenitor cells (HSPCs), erythroid cells, and CD4⁺ T cells (Supplemental Fig. S1B). The expression of *miR-99b~125a* miRNAs (hsa19) is higher in megakaryocytes, CD34⁺ HSPCs, and granulocytes as compared with the other blood lineages (Supplemental Fig. S1C). A previously published data set confirmed this expression pattern in murine cells (Petriv et al. 2010).

Both *miR-99a/100~125b* tricistrons are embedded in the intron of long intervening noncoding RNA (lincRNA) host genes (hsa11, *MIR100HG*; hsa21, *LINC00478*) (Fig. 1A). Quantification of primary miRNA/lincRNA transcripts in AMKL cell line CMK showed the same expression level of

the primary miRNAs of each tricistron and their lincRNA host gene (Supplemental Fig. S1D). Altogether, this suggests that miRNAs of the hsa11 and hsa21 tricistrons are produced from a single primary transcript, including the lincRNA host genes.

miR-99a~125b-2 enhances megakaryopoiesis at the expense of erythropoiesis

The coordinated expression as a polycistronic message in HSPCs and megakaryoblasts suggests a common function of hsa11/hsa21 tricistronic miRNAs in these cells. To dissect the functional contribution of each miRNA within the hsa21 tricistron and their combination during hematopoiesis, we cloned lentiviral constructs containing single miRNAs (*miR-99a*, *let-7c*, and *miR-125b-2*), the *miR-99a/let-7c* bicistron, or a combined cassette of the whole hsa21 *miR-99a~125b-2* tricistron. In human cord blood (CB) CD34⁺ HSPCs or MV4:11 cells, our lentiviral constructs increased expression of these miRNAs within a physiological range (Supplemental Fig. S1E–H). During megakaryocytic in vitro differentiation, we observed a remarkable expansion of cells upon *miR-125b-2* and *miR-99a~125b-2* overexpression (Fig. 1C). In contrast, *let-7c* or the *miR-99a/let-7c* bicistron had an opposite effect of impairing cell growth. *miR-99a* alone showed negligible effects. Similarly, megakaryocytic colony-forming unit (CFU-MK) assays indicated the expansion of CFU-MKs upon *miR-125b-2* expression either alone or in the context of the hsa21 *miR-99a~125b-2* tricistron (Fig. 1D; Supplemental Fig. S1I).

In medium promoting megakaryocytic and erythroid differentiation, CD34⁺ HSPCs expressing *miR-125b-2* or *miR-99a~125b-2* displayed a higher growth rate with increased differentiation into CD41⁺ megakaryocytes (Fig. 1E–G). *miR-99a~125b-2* decreased hemoglobinization and differentiation into CD235a⁺ erythroid cells (Fig. 1F–G). The block of erythroid development by the tricistron was even more aggravated in human fetal liver (FL) HSPCs (Supplemental Fig. S1J). This perturbed differentiation was preceded by increased megakaryocytic and decreased erythroid gene expression in CD34⁺ HSPCs after transduction (Fig. 1F). Moreover, when transduced murine lineage-depleted (Lin[−]) bone marrow (BM) cells (enriched for HSPCs) were cultured in stem cell expansion medium containing SCF, TPO, FGF, and IGF2, we observed spontaneous differentiation of *miR-125b-2* or *miR-99a~125b* tricistron-transduced cells into CD41⁺ megakaryocytic cells (Fig. 1H; Supplemental Fig. S1K).

Taken together, these data confirm previous observations that *miR-125b-2* is a positive regulator of megakaryopoiesis (Klusmann et al. 2010b; Emmrich et al. 2012). Moreover, we show for the first time that when embedded in its tricistronic context, *miR-125b*-driven megakaryocytic differentiation is further intensified by a block of erythroid differentiation.

The miR-99a~125b-2 phenotype is a cooperative effect of all three miRNAs

To test the genetic interaction of the miRNAs during megakaryopoiesis in an unbiased fashion, we applied

red–green–blue (RGB) marking (Weber et al. 2011). By mixing red, green, and blue, four mixed colors can be obtained, each representing a distinct color combination. We assigned each miRNA to one color: *miR-125b-2* to red, *let-7c* to blue, and *miR-99a* to green (Fig. 2A). Lentiviral constructs were pooled and transduced into human CD34⁺ HSPCs or murine FL Lin[−] HSPCs. Flow cytometric analysis demonstrated seven distinguishable populations resembling all possible miRNA combinations in equal starting amounts (Fig. 2B; Supplemental Fig. S2A). Monitoring the growth of the seven populations during megakaryocytic in vitro differentiation revealed

that *miR-125b-2*, *miR-99a/miR-125b-2*, and *miR-99a/let-7c/miR-125b-2* provided a growth advantage in both the human and murine cells (Fig. 2C,D). Correspondingly, in colony-forming assays, murine Lin[−] HSPCs containing *miR-125b-2* developed a greater number of and larger-sized colonies (Fig. 2E). Strikingly, with each round of replating, white colonies overexpressing all three miRNAs became increasingly dominant (Fig. 2E,F).

Thus, RGB marking demonstrated that *miR-125b-2* was mainly responsible for the growth advantage. However, only the combination of all three miRNAs could sustain this proliferative advantage over time.

Figure 2. *miR-99a/100~125b* miRNAs have a cooperative phenotype. (A) Schematic diagram showing the mixing spectra of RGB marking and the color assignments of *miR-99a*, *let-7c*, and *miR-125b-2*. Adapted with permission from Macmillan Publishers Ltd.: Nature Medicine (Weber et al. 2011), © 2011. (B) Experimental outline of RGB marking to quantify genetic interaction. (C,D) Diagrams showing the number of miRNA-transduced human (n = 3) (C) and murine (n = 4) (D) cells after megakaryocytic in vitro differentiation (day 8) with and without 1 ng/mL TGFβ1 in relation to the starting point (day 0) and the empty vector-transduced control cells (ctrl), measured by flow cytometry. (E, left panel) Merged microscopic fluorescence images of serial replatings of mouse FL cells. The right panel shows microscopic fluorescence images of the first replating of mouse FL cells treated with 1 ng/mL TGFβ1. Each fluorescent color was photo-acquired on day 11 separately using a BZ 9000 (Keyence) for subsequent image processing and merging with Biorevo software (Keyence). Colors represent distinct miRNA combinations: *miR-125b-2* (red), *miR-99a* (green), *let-7c* (blue), *miR-99a/miR-125b-2* (yellow), *miR-99a/let-7c* (turquoise), *let-7c/miR-125b-2* (purple), and *miR-99a/let-7c/miR-125b-2* (white). Representative images from n = 4 independent experiments are shown. (F) Cumulative number of colonies per round of plating. (C–F) Data are presented as mean ± SD.

The *miR-99a~125b-2* tricistron expands HSCs and HSPCs in vivo

Next, we investigated the effect of the miRNA tricistron in competitive repopulation assays in vivo. We transplanted lentivirally transduced Lin[−] BM cells into lethally irradiated syngenic recipients. *miR-125b-2* and *miR-99a~125b-2* overexpression conferred a competitive advantage to the cells, leading to a gradual increase of chimerism in the mononuclear cell fraction of the peripheral blood (PB). In contrast, nonsilencing shRNA control in the *miR-30* context (ctrl) and the *miR-99a/*

let-7c bicistron conferred a competitive disadvantage (Fig. 3A). Total platelet (Fig. 3B) and white blood cell (WBC) (data not shown) counts were significantly increased by *miR-125b-2* and *miR-99a~125b-2*. The fraction of GFP⁺ cells and the overall BM cellularity were similarly elevated (Supplemental Fig. S3A,B). Of note, we detected a significant expansion of the LSK cells and long-term (LT) HSCs (CD34[−] LSKs) as well as CD41⁺ megakaryocytic progenitors (MPs) exclusively in the marrow of *miR-99a~125b-2*-transplanted mice (Fig. 3C–F). As previously described, we also observed a lineage skewing

Figure 3. The *miR-99a~125b-2* cluster expands immature hematopoietic progenitors in vivo. (A) Percentage of GFP⁺ cells in the PB of recipient mice reconstituted with transduced Lin[−] HSPCs from syngenic donors at the indicated time points (ctrl, *n* = 14; *miR-125b-2*, *n* = 10; *miR-99a/let-7c*, *n* = 7; tricistron, *n* = 17). (B) PB platelets of the same mice as in A measured on week 24 after transplantation. (C) CD41⁺-expressing cells. (D) Representative flow cytometry plots. (E) Percentage of viable GFP⁺ LSK cells. (F) CD34[−] of LSK cells in the BM of the same mice as in A measured on week 24 after transplantation. (G) Percentage of GFP⁺ cells in the PB of secondary recipient mice reconstituted with transgenic whole BM of primary recipients from A (ctrl, *n* = 6; *miR-125b-2*, *n* = 5; *miR-99a/let-7c*, *n* = 5; tricistron, *n* = 6). (H) WBC counts. (I) Macroscopic images of bones (*top* panels) and of pellets from flushed BM samples before red blood cell lysis (*bottom* panel). (J) Representative LSK flow cytometry plots. (K) Percentage of viable GFP⁺ LSKs. (L) CD34[−] of LSK cells in the BM of the same mice as in E on week 16 after transplantation. (A–K) Data are presented as mean ± SEM. (B–F, H–L) Values for each mouse are shown. The black horizontal line indicates mean. (A–K) (*) *P* < 0.05; (**) *P* < 0.01. (A–L) (*miR-99a~125b-2*; (ctrl) nonsilencing miRNA.

toward the myeloid lineage by *miR-125b-2* (Bousquet et al. 2010; Guo et al. 2010; O'Connell et al. 2010) and *miR-99a~125b-2* (data not shown) in the BM.

Upon secondary transplantation of whole BM from primary recipients, *miR-99a~125b-2*-reconstituted mice showed little change in their chimerism over time. In contrast *miR-125b-2*-transduced GFP⁺ cells were out-competed (Fig. 3G). WBC, LSK, and LT-HSC expansion remained only in *miR-99a~125b-2* recipients, as evidenced by the paler femur and tibia and flow cytometric analyses (Fig. 3H–L). Thus, the competitive advantage conferred by *miR-125b-2* is sustained in the tricistronic context of *miR-99a~125b-2*.

HOXA10 binds and transactivates hsa21 and hsa11 miR-99a/100~125b tricistrons

Quantification of primary miRNA/lincRNA transcripts suggested that miRNAs of *hsa11* and *hsa21* tricistrons are

produced from a single primary transcript, including the lincRNA host genes (Supplemental Fig. S1D). Three common transcription start sites (TSSs) for the *miR-99a~125b-2* miRNAs were previously predicted (Fig. 1A; Marson et al. 2008). Similarly, the *miR-100~125b-1* tricistron harbors one common TSS for the host gene and all miRNAs. All predicted sites could be confirmed by 5'RACE-PCR (Supplemental Fig. S4A). In lentiviral reporter assays, the promoter adjacent to TSS2 among the *hsa21* TSSs displayed the highest activity in CMK cells with high endogenous miRNA expression (Fig. 4A). This suggests that expression of the *miR-99a~125b-2* tricistron is mainly controlled by this promoter region.

Identification of the active TSSs for *miR-99a/100~125b* tricistrons allowed mapping of transcription factor-binding sites (−5000 base pairs [bp] upstream of to +1000 bp downstream from *hsa11* TSS1 and *hsa21* TSS2). Mulan software predicted HOX-binding sites for both TSSs, phylogenetically conserved across seven species (Ovcharenko

Figure 4. *miR-99a/100~125b* clusters are transactivated by *HOXA10*. (A) Reporter assays in CMK and K562 cells. The empty TK-GFP and a vector without the TK promoter served as negative controls. The locations of TSS1, TSS2, and TSS3 are shown in Figure 1A. For each TSS, candidate promoters were amplified from genomic regions adjacent to the TSS (for TSS3, two candidate promoter fragments, TSS3-1 and TSS3-2, were amplified and tested). Mean fluorescence intensities (MFIs) were determined by flow cytometry for GFP ($n = 2$). (B) Correlation plots and statistics of *HOXA10* and miRNA expression in NB4, NOMO-1, THP-1, Kasumi-1, Jurkat, K562, M-07e, Meg-01, CMK, and CMY cells measured by qRT-PCR. (C,D) ChIP analysis in CMK and Meg-01 cells for *HOXA10* enrichment (C) or acetylated Histone H3 (H3Ac) (D) at predicted binding sites (bs) in experimentally validated *hsa21* TSS2 (*miR-99a~125b-2*) and *hsa11* TSS1 (*miR-100~125b-1*). Fold enrichment over background (IgG control) is shown ($n = 2$). (E) Luciferase reporter assays in 293T cells. The empty pGL4.1 and a 3000-bp fragment +1500 bp downstream from *hsa21* TSS2 served as negative controls ($n = 2$). Relative luminescence units (RLUs) were determined by normalizing firefly to renilla luciferase activity. HOX-binding sites (purple) and PBX-binding sites (blue) are indicated. (Left) The bold black bar in the schemes indicates the size and location of the cloned promoter fragment in relation to the TSS (arrow). (F) qRT-PCR expression analysis of *miR-99a~125b-2* miRNAs in *HOXA10*-transduced MV4:11 cells or in sh-*HOXA10*-transduced CMK cells relative to empty vector-transduced (MIGR1) or control vector-transduced (sh-SC) cells. (G) Flow cytometric analysis of megakaryocytic in vitro differentiation of *HOXA10/PBX1*-transduced CB CD34⁺ HSPCs ($n = 1$). (H) Annexin V/7-AAD staining of *HOXA10/PBX1*-transduced CB CD34⁺ HSPCs on day 7 of mixed megakaryocytic/erythroid differentiation treated with 1 ng/mL TGFβ1. (A–H) Data are presented as mean $\pm$ SD. (*) $P < 0.05$; (**) $P < 0.01$.

et al. 2005; data not shown). HoxA10 was previously shown to expand primitive HSCs and MPs, thereby acting as a leukemogenic transcription factor (Thorsteinsdottir et al. 1997; Bjornsson et al. 2001; Magnusson et al. 2007). We observed a significant positive correlation between the expression of *HOXA10* and the mature miRNAs for each *miR-99a/100~125b* miRNA except *let-7a-2*, which has two more isomers outside of the tricistrons (Fig. 4B). Particularly in AMKL blasts, *HOXA10* is highly expressed (data not shown). Chromatin immunoprecipitation (ChIP) in two AMKL cell lines (CMK and Meg-01) with high miRNA and *HOXA10* levels confirmed chromatin occupancy of *HOXA10* at both promoter regions (Fig. 4C). The promoter regions occupied by *HOXA10* were enriched for acetylated Histone H3, a typical epigenetic mark of transcriptional active promoters (Fig. 4D). Concordantly, ectopic expression of *HOXA10* increased the activity of a hsa21 promoter fragment containing two HOX sites (−18 bp and +192 bp) and a more distal PBX site (+866 bp) in 293T cells (Fig. 4E). Fragment deletion analysis underscored the necessity of the PBX site and the HOX site +192 bp downstream from the TSS (Fig. 4E).

Ectopic *HOXA10* expression in MV4:11 cells up-regulated the levels of mature *miR-99a*, *miR-100*, and *miR-125b* but not the *let-7* members (Fig. 4F; Supplemental Fig. S4B). *let-7* has several homologs, and its expression underlies post-transcriptional regulation, which might explain this finding (Hagan et al. 2009; Chen et al. 2011). Conversely, shRNA knockdown of *HOXA10* in CMK cells led to decreased *miR-99a*, *let-7c*, and *miR-125b* expression (Fig. 4F; Supplemental Fig. S4C). As previously reported, ectopic expression of *HOXA10* and its cofactor, *PBX1*, promoted the expansion of CD41⁺ MPs while inhibiting erythroid development (Fig. 4G; Magnusson et al. 2007). These data provide an explanation for the physiologic expression of *miR-99a/100~125b* miRNAs in HSPCs and aberrant expression in malignant megakaryoblasts.

miR-99a/100~125b target TGFβ pathway activators and Wnt repressors

To identify the downstream effectors targeted by the *miR-99a/100~125b* tricistrons, we performed global gene expression profiling of human CD34⁺ HSPCs transduced with single miRNAs or the *miR-99a~125b-2* tricistron. Target transcripts (predicted by at least three independent prediction programs in miRecords) (Xiao et al. 2009) of each miRNA were strongly repressed by the *miR-99a~125b-2* tricistron (Fig. 5A; Supplemental Table S1). We hypothesized that the combinatorial action of the three miRNAs does not converge on individual targets but rather on gene expression programs or signaling cascades. Therefore, we analyzed by integrated pathway architecture which signaling pathways are enriched for down-regulated targets of *miR-99a~125b-2* (Supplemental Table S2). Positive effectors of the TGFβ pathway were targeted on all layers of the signaling cascade: receptors (TGFβ receptor I [*ALK5*], activin A receptor *ACVR1C* [*ALK7*], and BMP receptors *BMPR1A* [*ALK3*] and *BMPR2*),

transmitters, and/or transcription factors (*SMAD2* and *SMAD4*) (Fig. 5B; for quantitative RT-PCR [qRT-PCR] validation, see Supplemental Fig. S5A). To promote their effects, TGFβ superfamily ligands (TGFβ, Activin, Nodal, and BMP) bind to type I (e.g., TGFβR1) and type II (e.g., TGFβR2) receptors, which together form an activated complex and phosphorylate regulatory SMADs (R-SMADs: *SMAD1–3*, *SMAD5*, and *SMAD8*). R-SMADs complex with common mediator SMAD (co-SMAD: *SMAD4*) and several lineage-specific cofactors to induce transcription in a cell context-dependent manner (Fig. 5B; Moustakas and Heldin 2009). TGFβ, Activins, and Nodals signal through *SMAD2/3*, and BMP signals through *SMAD1/5/8*. In the hematopoietic system, TGFβ1 ensures stem cell homeostasis by keeping HSCs in quiescence and blocking their transition into faster-cycling short-term (ST) HSCs (Pietras et al. 2011). TGFβ1 stimulates differentiation of late erythroid and myeloid progenitors but blocks megakaryopoiesis (Jacobsen et al. 1991; Fortunel et al. 1998). This constitutes a negative feedback loop, as megakaryoblasts and megakaryocytes secrete active TGFβ1, while platelets' α granules are the major source of TGFβ1 (Fava et al. 1990; Fortunel et al. 2000). Thus, we reasoned that the observed expansion of HSPCs, stimulation of megakaryopoiesis, and blocking of erythropoiesis by *miR-99a~125b-2* could be mediated by inhibition of TGFβ1 signaling. Deregulation of *miR-99~125* tricistrons could provide AMKL blasts a mechanism to evade the growth inhibitory function of TGFβ.

Gene set enrichment analysis (GSEA) confirmed the inverse correlation of *miR-99~125* with TGFβ pathway genes (Supplemental Fig. S5B). Down-regulation of the predicted targets was validated at the protein level in transduced MV4:11 and THP-1 cells (Fig. 5C). Moreover, stable inhibition of all three tricistron miRNAs alone (SP-99, SP-let7, and SP-125) or the tricistron (SP-TRI) using lentiviral sponge (SP) constructs (Emmrich et al. 2013) in Meg-01 cells up-regulated the target proteins (Fig. 5C; Supplemental Fig. S5C,D). Direct miRNA regulation of putative 3' untranslated region (UTR) target sites was validated by luciferase reporter assays (Fig. 5D). Of note, luciferase reporter assays and Western blot analyses confirmed that targets of only one miRNA showed at least equal regulation by the tricistron compared with one miRNA alone. Conversely, targets with binding sites for two miRNAs, such as *ACVR1C* or *SMAD2*, were targeted more efficiently by the tricistron. Thus, *miR-99a/100*, *let-7*, and *miR-125b* converge in repressing targets of the TGFβ pathway.

In contrast to TGFβ signaling, canonical Wnt signaling induces self-renewal and proliferation of HSCs in a dose-dependent manner (Luis et al. 2011). Bioinformatics predicted targeting of the core component of the destruction complex *adenomatous polyposis coli* (*APC*) and its homolog, *APC2*, by *miR-99a~125b-2* miRNAs. When Wnt signaling is inactive, β-catenin is bound and phosphorylated by the destruction complex composed of AXIN1, GSK3β, and APC, leading to its degradation. Inhibition of the destruction complex upon binding of Wnt ligands to its membrane-bound receptor results in the accumu-

Figure 5. *miR-99/100~125* miRNAs target the TGF β and Wnt pathways. (A) Hierarchical clustering of *miR-99/100* targets (green box), *let-7* targets (blue box), and *miR-125* targets (red box) from miRNA-transduced human CB CD34⁺ HSPCs on day 7 of megakaryocytic differentiation ($n = 2$). The normalized enrichment score (NES) of each target gene set compared with the control calculated by GSEA is indicated. (*) $P < 0.05$; (**) $P < 0.01$. (B) Schematic diagram of the TGF β and Wnt pathways. *miR-99~125* putative target genes are framed in red. (C) Western blots of the indicated proteins in miRNA-transduced MV4:11 or THP-1 cells and SP-transduced Meg-01 cells. (D) Luciferase reporter assays in 293T cells ($n = 3$) with 3' UTR fragments harboring color-indicated wild-type miRNA-binding sites in relation to the nonsilencing miRNA (ctrl). The presence or absence of binding sites corresponded with the regulatory effect. (Green) *miR-99/100*; (blue) *let-7*; (red) *miR-125*. The black line indicates the full-length 3' UTR. (Left) The bold black bar in the schemes indicates the size and location of the cloned UTR fragment. (D) Data are presented as mean $\pm$ SD. (A,C,D) (tricistron) *miR-99a~125b-2*; (ctrl) nonsilencing miRNA.

lation and nuclear translocation of β -catenin, where it forms a complex with TCF/LEF to induce transcription (Logan and Nusse 2004). In tricistron-transduced cells, we detected decreased protein levels of APC and APC2 (Fig. 5C). *APC2* is targeted by all three miRNAs. *APC* is targeted by *let-7* and *miR-125*. Consistent with this, reporter assays for *APC* demonstrated binding of *let-7c* and *miR-125b-2* alone or with stronger effect in the context of the tricistron (Fig. 5D).

Wnt pathway modulation correlates with the *miR-99a~125b-2* megakaryocytic phenotypes

We sought to examine whether Wnt activation is a central function of *miR-99a~125b-2*, conferring a growth advantage to normal HSPCs and malignant AML blasts. Wnt activation is a common feature of several forms of cancer, including leukemia, and targeting Wnt signaling was shown to be an attractive treatment strategy in AML

(Klaus and Birchmeier 2008; Wang et al. 2010). We first tested whether genetically enhancing Wnt signaling by *miR-99a~125b-2* could ameliorate pharmacologic Wnt inhibition. Treatment of MV4:11 cells with Wnt inhibitor ICG-001, which disrupts the β -catenin/CBP interaction (Emami et al. 2004), or the reversible COX inhibitor indomethacin (Indo), which suppresses β -catenin expression (Hawcroft et al. 2002; Goessling et al. 2009), reduced proliferation and colony-forming capacity while inducing apoptosis (Fig. 6A–C; Supplemental Fig. S6A–C). These effects were rescued by enforced expression of *miR-*

99a~125b-2 or shRNA-mediated knockdown of the *miR-125/let-7* common target *APC* (Fig. 6A–C; Supplemental Fig. S6A–C). Inversely, we asked whether pharmacologic Wnt inhibition would cooperate with *miR-99~125* inhibition in reducing leukemic growth in AMKL. Stable inhibition of *miR-125* or *miR-99~125* in CMK cells using SP constructs reduced proliferation and colony formation but did not induce apoptosis (Fig. 6D–F). K562 cells with low *miR-99a/100~125b* expression (Supplemental Fig. S7B) were not affected by the sponge constructs (Supplemental Fig. S6D–F). Treatment of nonsilencing sponge

Figure 6. *miR-99a/100~125b* miRNAs augment Wnt signaling. (A) Viability of miRNA- or shRNA-transduced MV4:11 cells treated with 10 μ M ICG-001, relative to nonsilencing miRNA (ctrl; $n = 2$). (Inset) shRNA knockdown validation by Western blotting. (B) Methylcellulose colony assay of transduced MV4:11 cells ($n = 2$). (C) Annexin V/7-AAD staining after 4 d of ICG-001 treatment ($n = 2$). (D) Fraction of SP-transduced GFP⁺ cells competing with untransduced cells relative to the control (SP-sc). (E) Methylcellulose colony-forming assays of SP-transduced CMK cells. (F) Annexin V/7-AAD staining of SP-transduced CMK cells 5 d after selection. (G) Fraction of SP-transduced GFP⁺ cells competing with untransduced cells relative to the control (SP-sc) upon ICG-001 treatment. (H) Methylcellulose colony-forming assays of ICG-001-treated or untreated SP-transduced CMK cells. (I) Annexin V/7-AAD staining of SP-transduced CMK cells after 5 d of treatment with 10 μ M ICG-001 ($n = 3$). (J) Cell number in relation to nonsilencing miRNA (ctrl). (K) Percentage of CD41⁺ / CD42b⁺ megakaryocytes of tricistron-transduced CB CD34⁺ HSPCs treated with either 1 μ M ICG or 50 μ M Indo ($n = 2$). (L) Flow cytometric analysis of Ser45 phosphorylation of β -catenin during combined megakaryocytic/erythroid in vitro differentiation of miRNA-transduced CB CD34⁺ HSPCs 1 h after stimulation with 200 ng/mL Wnt3a. Isotype-stained nonsilencing miRNA (ctrl)-transduced cells are shown. (M) Western blots of activated (unphosphorylated) β -catenin in miRNA-transduced MV4:11 cells. (N) Luciferase reporter assay using a TCF/LEF response element (TOPFlash) and a mutated version (FOPFlash) in untreated, Wnt3A-treated, and BIO-treated 293T cells, respectively, cotransfected with the indicated miRNAs ($n = 4$). RLU are presented normalized to Renilla luciferase intensities. (A–C, J–N) (tricistron) *miR-99a~125b-2*; (ctrl) nonsilencing miRNA. (A–N) Data are presented as mean $\pm$ SD. (*) $P < 0.05$; (**) $P < 0.01$; (ns) not significant.

(SP-sc) control-transduced CMK and Meg-01 cells with ICG-001 reduced their proliferation and colony-forming capacity while inducing apoptosis. In all assays, *miR-99~125* knockdown by SP-TRI synergized with ICG-001 and aggravated its effects (Fig. 6G–I; Supplemental Fig. S6G–I).

Next, we aimed to modulate Wnt activity to recapitulate or mitigate *miR-99a~125b-2*-mediated expansion of MPs. Wnt3a, one of 19 distinct Wnt ligands, has been reported to induce Wnt signaling in the hematopoietic system (Luis et al. 2012). Similar to *miR-99a~125b-2*, supplementation with Wnt3a during megakaryocytic differentiation increased the total number of cells (Supplemental Fig. S6J). These observations are in accordance with a previous report (Macaulay et al. 2013). Inversely, Wnt inhibition using ICG-001 or Indo reduced the stimulatory effects of *miR-99a~125b-2* on in vitro megakaryopoiesis (Fig. 6J–K).

To study Wnt activation by *miR-99a~125b-2* on the molecular level, we quantified phosphorylated β -catenin in transduced CD34⁺ HSPCs. We found that degradation-primed phosphorylated β -catenin (Ser45) was decreased upon ectopic *miR-99a~125b-2* expression (Fig. 6L). In contrast, levels of β -catenin in its active (unphosphorylated) form were elevated in tricistron-transduced cells, as confirmed by Western blotting (Fig. 6M; Supplemental Fig. S6K). Up-regulation of Wnt downstream targets in *miR-99a~125b-2*-transduced MV4:11 cells, such as cyclins, *BTRC*, *BCL-9*, and *LEF-1*, was confirmed by qRT-PCR (Supplemental Fig. S6L). Moreover, in 293T cells, *miR-99a~125b-2* augmented Wnt activation by GSK3 β inhibitor BIO and Wnt3A, as evidenced by the increased luciferase activity of a TCF4 consensus binding site element (TOPFlash) but not of a mutated version (FOPFlash) (Fig. 6N).

In conclusion, *miR-99/100~125b* tricistrons activated Wnt signaling by inhibiting *APC/APC2*, stabilizing cytoplasmic β -catenin, and increasing activated β -catenin. Pharmacologic or genetic Wnt activation could partially mimic, whereas Wnt inhibition could mitigate, *miR-99a~125b-2*-mediated expansion of MPs. Accordingly, *miR-99~125* knockdown and Wnt inhibition synergized to induce growth arrest and apoptosis in leukemic cell lines.

miR-99a~125b-2 rescues TGF β -mediated apoptosis, cell cycle arrest, and blocking of megakaryopoiesis

Our data suggest that up-regulation of *miR-99a~125b-2* might represent a strategy of leukemic blasts to escape TGF β 1-induced apoptosis and cell cycle arrest, as it has been demonstrated for other oncogenes (Massague 2008). Ectopic *miR-125b-2* and *miR-99a~125b-2* expression or shRNA-mediated knockdown of *miR-125/let-7* common target *SMAD4* in TGF β 1-sensitive MV4:11 and THP-1 cells with low endogenous *miR-99/100~125b* expression (Supplemental Fig. S7A,B) conferred resistance against the growth-suppressing and proapoptotic effects of TGF β 1 (Fig. 7A,B; Supplemental Fig. S7C). In methylcellulose CFU assays, reduction of colony formation upon TGF β 1

treatment was almost neutralized by *miR-99a~125b-2* (Fig. 7C; Supplemental Fig. S7D).

Next, we analyzed the effects of *miR-99a~125b-2* on TGF β signaling in primary CD34⁺ HSPCs. TGF β 1 is released by platelets (Fava et al. 1990; Fortunel et al. 2000) and blocks megakaryopoiesis while stimulating differentiation of late erythroid and myeloid progenitors (Jacobsen et al. 1991; Fortunel et al. 2000). As expected, TGF β 1 treatment strongly reduced the number of viable cells during megakaryocytic in vitro differentiation. However, *miR-99a~125b-2*-transduced or sh-SMAD4-transduced HSPCs expanded 25-fold and 13-fold, respectively, as compared with controls (Fig. 7A). In comparison, cells treated with specific TGF β receptor kinase inhibitor SB43152 (ALK4/5/7 inhibitor) expanded 17-fold. The cytoprotectivity of *miR-125b-2* and *miR-99a~125b-2* was associated with an abrogation of TGF β 1-induced apoptosis and a partial rescue of TGF β 1-induced cell cycle arrest during both megakaryocytic and combined megakaryocytic/erythroid differentiation (Fig. 7B,D; Supplemental Fig. S7E). This was also observed upon activation of the *miR-99/100~125b* tricistrons by ectopic expression of *HOXA10* and its cofactor, *PBX1* (Fig. 4H). The megakaryocytic differentiation block of TGF β 1 during combined erythroid/megakaryocytic in vitro differentiation was released by the *miR-99a~125b-2* tricistron, as assessed by the percentage of CD41⁺ (Fig. 7E) and CD36⁺ (marker for erythroid progenitors and MPs) (Supplemental Fig. S7F) cells. The rescue by *miR-99a~125b-2* expression was stronger than by ALK inhibitor SB43152 (Fig. 7E). Similarly, TGF β 1-mediated suppression of CFU-MK formation was almost neutralized by *miR-99a~125b-2* expression (Fig. 7C).

RGB marking indicated that the resistance to TGF β 1 can be largely attributed to *miR-125b-2*. Each combination containing *miR-125b-2* led to expansion of cells when either human or murine HSPCs were treated with TGF β 1 (Fig. 2C,D). However, upon replating of TGF β 1-treated cells, white colonies (i.e., *miR-99a/let-7c/miR-125b-2*-transduced) became prevalent (Fig. 2E; Supplemental Fig. S2B).

At the molecular level, *let-7c*, *miR-125b*, and the tricistron reduced total SMAD2 protein and inhibited phosphorylation of SMAD2 following TGF β 1 stimulation (Fig. 7F). Intracellular flow cytometry staining confirmed that *miR-125b* and the tricistron reduced TGF β 1-mediated phosphorylation (activation) of SMAD2/3 (Fig. 7G,H). In concordance with this observation, *miR-125b* and *miR-99a~125b-2* repressed transcriptional activity of TGF β pathway downstream effector SMAD. Treatment with TGF β 1 at intermediate and high levels resulted in significantly lower activity of a reporter plasmid (PAI-1 promoter) containing 12 repeats of the SMAD-responsive element CAGA (Dennler et al. 1998) in *miR-125b* and *miR-99a~125b-2* transfected 293T cells (Fig. 7I). A different reporter with four repeats of SMAD-binding elements (SBE4x) yielded similar results (data not shown). In addition, downstream target genes of the TGF β pathway, such as *FOS*, *ID1*, and *ID2*, were repressed in *miR-99a~125b-2*-transduced MV4:11 cells treated with TGF β 1 (Supplemental Fig. S6L).

Figure 7. *miR-99a/100~125b* miRNAs antagonize TGFβ1 function. (A) The number of miRNA-transduced or sh-SMAD4-transduced MV4:11 cells (left) or human CB CD34⁺ HSPCs (right) during megakaryocytic in vitro differentiation, treated with the indicated concentrations of TGFβ1, normalized to nonsilencing miRNA (ctrl)-transduced cells ($n = 3$). (Inset) shRNA knockdown validation by Western blotting. Nonsilencing miRNA (ctrl)-transduced CD34⁺ HSPCs treated with 10 μ M TGFβ inhibitor SB43152 are included. (B) Annexin V/7-AAD staining of miRNA-transduced or sh-SMAD4-transduced MV4:11 cells on day 4 (left) or miRNA-transduced or sh-SMAD4-transduced CB CD34⁺ HSPCs (right) on day 7 of combined megakaryocytic/erythroid differentiation, treated with the indicated concentrations of TGFβ1 in comparison with untreated controls (ctrl; $n = 3$). (C) Methylcellulose colony-forming assays of miRNA-transduced or sh-SMAD4-transduced MV4:11 cells (left) or the number of CD41⁺ CFU-MKs of miRNA-transduced CB CD34⁺ HSPCs (right) treated with the indicated concentrations of TGFβ1 in comparison with untreated nonsilencing miRNA (ctrl)-transduced cells ($n = 3$). (D) BrdU incorporation of miRNA-transduced CB CD34⁺ HSPCs on day 5 of combined megakaryocytic/erythroid differentiation ($n = 3$) in comparison with nonsilencing miRNA (ctrl). (E) Dot plots of flow cytometric analysis of miRNA-transduced CB CD34⁺ HSPCs on day 11 of combined megakaryocytic/erythroid in vitro differentiation treated with 1 ng/mL TGFβ1 for the last 72 h ($n = 2$). (F) Western blots of the indicated proteins in miRNA-transduced MV4:11 cells with or without 10 ng/mL TGFβ1. (G) Phosflow analysis of Smad2/3 phosphorylation in miRNA-transduced MV4:11 cells stimulated with TGFβ1, shown as MFI. (H) Phosflow analysis of Smad2/3 phosphorylation during megakaryocytic/erythroid in vitro differentiation of miRNA-transduced CB CD34⁺ HSPCs. Cells were stimulated for 1 h with TGFβ1. Isotype-stained and untreated nonsilencing miRNA (ctrl)-transduced cells are shown as controls. (I) Luciferase reporter assay using a SMAD response element (PAI-I promoter) in TGFβ1-treated 293T cells cotransfected with the indicated miRNAs ($n = 3$). RLUs are presented in relation to the nonsilencing miRNA (ctrl). (J) Fraction of SP-transduced GFP⁺ K562 (left) and CMK (right) cells competing with untransduced cells relative to the control (SP-sc) treated with 10 ng/mL TGFβ1 ($n = 3$). (K) Annexin V/7-AAD staining of SP-transduced K562 (left) and CMK (right) cells after 5 d of treatment with 10 ng/mL TGFβ1 ($n = 3$). (L) Methylcellulose colony-forming assays of SP-transduced K562 (left) and CMK (right) cells treated with 10 ng/mL TGFβ1 ($n = 3$). [A–D, F–I] (tricitron) *miR-99a~125b-2*; (ctrl) nonsilencing miRNA. [A–L] Data are presented as mean $\pm$ SD. (*) $P < 0.05$; (**) $P < 0.01$.

Last, we wanted to determine whether the tricistron's effect might also be attributed to the other branches of the TGF β superfamily. However, leukemic growth of miRNA- or control-transduced MV4:11 cells was not affected by BMP4 or Activin A (Supplemental Fig. S7G–J). Activin A reduced the expansion of MPs during in vitro culture, while high levels of BMP4 slightly increased their proliferation (Maguer-Satta et al. 2003; Jeanpierre et al. 2008). Tricistron-transduced CD34⁺ HSPCs were resistant to both effects (Supplemental Fig. S7O). In concordance with this observation, *miR-99a~125b-2* reduced BMP4-mediated phosphorylation of SMAD1/8 (Supplemental Fig. S7L).

We conclude that *miR-99/100~125b* tricistrons block the TGF β pathway, thereby abrogating its effect on differentiation, apoptosis, and cell cycle arrest during megakaryopoiesis.

Inhibition of miR-99~125 miRNAs restores TGF β sensitivity in AMKL cell lines

If ectopic *miR-99a/100~125b* expression blocks the TGF β pathway, then inhibition of tricistron function should enhance the TGF β pathway and abrogate TGF β 1 resistance in AMKL. CMK and Meg-01 cells have high endogenous *miR-99a/100~125b* expression and are mainly TGF β -resistant. K562 cells served as negative controls, as they are also TGF β -resistant but have low *miR-99a/100~125b* expression (Supplemental Fig. S7A,B). CFU, proliferation, and apoptosis assays showed no response of SP-sc-transduced K562 cells to TGF β 1. As expected, SP-mediated inhibition of *miR-99/100*, *let-7*, or *miR-125* did not sensitize K562 cells to TGF β 1 (Fig. 7J–L). In contrast, blocking *miR-99/100*, *let-7*, or *miR-125* in CMK and Meg-01 cells significantly reduced in vitro growth, proliferation, cell cycle arrest, and colony formation in synergy with TGF β 1 (Fig. 7J–L; Supplemental Fig. S7K–N; for untreated SP-transduced CMK and K562 cells, see Fig. 6D–F; Supplemental Fig. S6D–F). The growth inhibitory effect, measured by GFP competition assays, was most pronounced in SP-125- and SP-TRI-transduced CMK and Meg-01 cells. A significant increase of apoptosis was observed only in SP-125-transduced and SP-TRI-transduced cells (Fig. 7K; Supplemental Fig. S7L). Thus, combined inhibition of *miR-99~125* miRNAs could sensitize TGF β -resistant CMK and Meg-01 cells to TGF β -mediated cell cycle arrest and apoptosis.

Inhibition of APC and SMAD4 efficiently mimics miR-99a~125b-2 in HSPCs

If the concerted activity of *miR-99a/100~125b* miRNAs on two pathways underlies the observed phenotype, then inhibition of single targets in one pathway may not fully recapitulate the *miR-99a/100~125b* tricistron's phenotype. To this end, we used superinfection of shRNA constructs directed to *APC* (marked with Venus) and *SMAD4* (marked with mCherry) to transduce and sort double-positive HSPCs. During in vitro megakaryopoiesis, simultaneous knockdown of *APC* and *SMAD4* more closely resembled the effect of the tricistron as compared

with knockdown of either gene alone (Fig. 8A). The same applied for abrogation of TGF β 1-induced cell cycle arrest and apoptosis during megakaryopoiesis (Fig. 8B,C). Finally, we tested the synergy of activating the TGF β pathway and inhibiting Wnt signaling to antagonize the tricistron in AMKL cells. Increasing doses of Wnt inhibitors ICG-001 or Indo greatly sensitized TGF β 1-resistant CMK and Meg-01 cells to TGF β 1 (Fig. 8D; Supplemental Fig. S8A,B), providing a novel option for combination treatment.

Discussion

Here, we unraveled a common regulatory function of *miR-99a/100*, *let-7*, and *miR-125b* homologs in the hematopoietic system. The miRNAs are encoded in two highly conserved *miR-99a/100~125b* tricistrons on hsa11 and hsa21. They are highly expressed in HSCs/HSPCs and AMKL, a very aggressive form of leukemia with poor prognosis (Creutzig et al. 2012). We demonstrate that the tricistrons are produced from one primary transcript transactivated by the stem cell regulator HOXA10. It is the concerted activity of all three tricistron miRNAs that leads to the expansion of HSCs and MPs. This is achieved by jointly blocking the TGF β pathway via repression of receptors and SMADs while elevating Wnt signaling via inhibition of the destruction complex (Fig. 8E). The TGF β and Wnt pathways are two major regulatory signaling cascades that inversely ascertain the balance between HSC self-renewal and proliferation on the one hand and quiescence and differentiation on the other hand.

TGF β ensures stem cell homeostasis by keeping HSCs in quiescence (Pietras et al. 2011) while inducing growth arrest and apoptosis in early HSPCs (Rorby et al. 2012). Thus, insensitivity to this inhibitory growth factor would render cells resistant to normal homeostatic mechanisms. This is a frequently observed mechanism in transformed hematopoietic cells to gain a growth advantage over their normal counterparts; e.g., the AML1/ETO fusion protein physically interacts with SMADs to disrupt SMAD-mediated transcription (Jakubowiak et al. 2000). Thus, overexpression of *miR-99~125* tricistrons constitutes a novel mechanism to evade the growth inhibitory function of TGF β , which can be exploited by leukemic cells. Megakaryoblasts secrete active TGF β 1, determining the requirement to disrupt this autoregulatory feedback loop during malignant transformation in AMKL. Strikingly, when *miR-99~125* were inhibited in AMKL cells, TGF β sensitivity was restored, opening the avenue for future therapeutic intervention.

However, the *miR-99a/100~125b* tricistrons not only render hematopoietic cells insensitive to inhibitory growth factors but also increase their sensitivity to Wnt signaling. This is achieved by down-regulation of key members in the destruction complex (*APC/APC2*). In contrast to TGF β , Wnt signaling is a positive regulator of self-renewal in HSCs and for megakaryopoiesis (Luis et al. 2012; Macaulay et al. 2013). When Wnt signaling is modestly enhanced, HSCs reconstitute better. However, a higher level of Wnt signaling results in failure to reconstitute irradiated recipient mice and multilineage

defects (Kirstetter et al. 2006). The deregulation of Wnt signaling as a causative factor in leukemogenesis has become more and more apparent (Klaus and Birchmeier 2008). We hypothesize that this careful titration of the optimal activation level of signaling cascades determines the necessity for three miRNAs within the tricistron to coevolve.

Thus, our study shifts the focus from proliferation- and apoptosis-related *miR-125* targets such as *Bak1*, *Puma*, *p53*, *Trp53inp1*, and *ST18* (for review, see Shaham et al. 2012) to a tricistron target gene set affecting crucial upstream signaling pathways. Our study is in accordance with previous studies on individual *miR-125* and *let-7* family members in other cellular systems that demonstrated targeting of TGF β or Wnt pathway genes. In

embryonic stem cells (ESCs), *miR-125a* targets *Dies1* to maintain strong BMP signaling and low to absent Activin/Nodal messaging. This keeps ESCs in an undifferentiated state (Parisi et al. 2012). *miR-125* isoforms can also repress *SMAD4* in human ESCs to favor neural commitment during neural conversion (Boissart et al. 2012). *let-7* family members inhibit *TGFBR1* to prevent endothelial-to-mesenchymal transition, while, in chicken embryos, down-regulation of *let-7* permits active ACVR2 to contribute to gastrulation (Bobbs et al. 2012; Chen et al. 2012).

We showed that *miR-125b* was responsible for the majority of the tricistron effects on the hematopoietic system; e.g., the tricistron recapitulated the *miR-125b* phenotype during human in vitro megakaryopoiesis. Thus,

Figure 8. *miR-99a/100~125b* tricistrons regulate HSPC homeostasis by shifting the balance between TGF β and Wnt signaling. (A,B) The number of miRNA- or shRNA-transduced CB CD34⁺ HSPCs ($n = 2$) during megakaryocytic in vitro differentiation relative to the control (nonsilencing miRNA [ctrl]). (B) TGF β 1 (1 ng/mL) was added to the culture. (C) AnnexinV/7-AAD staining on day 4 of megakaryocytic in vitro differentiation after treatment with 1 ng/mL TGF β 1. (D) The number of viable CMK cells upon treatment with increasing concentrations of ICG-001 in the presence or absence of 10 ng/mL TGF β 1 ($n = 4$). (E) Graphical model summarizing our study. By switching the balance between Wnt and TGF β signaling, the concerted action of *miR-99/100*, *let-7*, and *miR-125b* promotes sustained expansion of murine and human HSPCs in vitro or in vivo while favoring megakaryocytic differentiation. (A–D) Data are presented as mean $\pm$ SD. (*) $P < 0.05$; (**) $P < 0.01$.

despite targeting several common targets in the TGF β and Wnt pathway, *miR99/100* and *let-7* exert different effects on HSPCs than *miR-125b*. These observations are consistent with previous reports on the *miR-99b~125a* tricistron in the murine system (Guo et al. 2010; Gerrits et al. 2012). It was previously reported that *miR-125a* or *miR-125b* overexpression confers a competitive advantage to HSCs, leading to a gradual increase of chimerism in murine transplantation models (Guo et al. 2010; Ooi et al. 2010; Enomoto et al. 2011). When γ -retroviral vectors were used, which increased *miR-125* expression level by 500-fold to several thousand-fold, development of myeloproliferative disease (MPD) and leukemia was observed (Gerrits et al. 2012; for discussion, see O'Connell et al. 2010). Using a lentiviral system with a SFFV promoter-driven miRNA cassette, we achieved expression levels comparable with those seen in AMKL. The *miR-99a*, *let-7c*, and *miR-125b* expression level in tricistron-transduced cells was equal to or lower than that in single miRNA-transduced cells. This excludes the possibility that the observed tricistron phenotype reflects a *miR-125* dose-dependent phenomenon. Similar to other recent studies using lentiviral systems, we observed a competitive repopulation advantage and myeloid lineage bias but no MPD or leukemia from *miR-125b-2*- and *miR-99a~125b-2*-transduced Lin⁻ BM cells in vivo (Surdziel et al. 2011). Interestingly, the competitive advantage conferred by *miR-125b-2* was only sustained in the tricistronic context of *miR-99a~125b-2*. Only the tricistron was able to expand the LSK and LT-HSC compartment in primary and secondary recipients. The same applies to RGB marking, where only *miR-99a*, *let-7c*, and *miR-125b-2* together allowed colony formation for more than two rounds of replating. Thus, *miR-125b* enhances proliferation of HSCs and MPs by negatively regulating anti-proliferative and proapoptotic genes; many of these genes are either part of the TGF β or Wnt pathway or downstream effectors of this pathway. If no leukemic lesions are acquired, the *miR-125b*-transduced HSC pool will exhaust. Tumor suppressor *let-7c* or *miR-99a/100* lacks those anti-apoptotic and proliferative target genes of *miR-125b*. In contrast, both miRNAs negatively regulate proliferative genes such as oncogenic *MYC*, *MYCN*, *MYCL1*, *RAS*, and *HMGA2* and TCF-responsive genes *CCND1* and *CCND2* (Johnson et al. 2005; Lee and Dutta 2007). These differences in the targetome might explain distinctive hematopoietic phenotypes of *let-7c*, *miR-99a/100*, and *miR-125b*. Our results indicate that *let-7* and *miR-99/100* are not sufficient to fully block TGF β or activate Wnt signaling. We hypothesize that *miR-99/100* and *let-7* assist *miR-125b* in suppressing TGF β pathway genes or the β -catenin destruction complex. By repressing additional proliferative targets, *miR-99/100* and *let-7* partially counteract *miR-125b*-induced hyperproliferation of HSCs, which confers a steady-state growth advantage and prevents exhaustion of *miR-99~125*-transduced HSCs.

Thus, *miR-99a/100~125b* tricistronic miRNAs converge in a combined phenotype in which *miR-99/100* and *let-7* add to or subtract from the hematologically

dominant *miR-125* phenotype. In addition, the interplay between *let-7* and *miR-125* via LIN28 proteins in HSPCs should not be neglected. While *LIN28B* represses *let-7* to maintain stemness and block erythroid development (Lee et al. 2013), high *miR-125* levels repress *LIN28A* (Chaudhuri et al. 2012). These are expected to add another layer of cross-talk between miRNAs in the *miR-99a/100~125b* tricistrons.

With a plethora of miRNAs organized in polycistrons and regulatory versatility by genetic interactions, we believe our study paves the way to integration of combined gene regulation by miRNA clusters in stem cell biology. Furthermore, Wnt and TGF β signaling also plays crucial roles in other developmental and cellular systems (Oshimori and Fuchs 2012), thus potentially extending the regulatory repertoire of *miR-99a/100~125b* tricistrons beyond hematopoiesis.

Overall, we explored a *HOXA10~miR-99a/100~125b*-TGF β /Wnt axis responsible for hematopoietic stemness, megakaryocytic development, and leukemogenesis (Fig. 8E). Our study holds promising potential for future treatment rationales of hematologic malignancies.

Materials and methods

Patient samples and cell lines

The AML-Berlin–Frankfurt–Münster study group (AML-BFM-SG, Hannover, Germany) provided all patient samples. CB HSPCs from donors were positively selected by labeling CD34-expressing cells with magnetic cell-sorting beads (Miltenyi Biotec). FL CD34⁺ HSPCs were purchased from Novogenic Laboratories. Culture conditions for maintenance, megakaryocytic, or megakaryocytic/erythroid in vitro differentiation of CD34⁺ HSPCs were described elsewhere (Klusmann et al. 2010a; Kumar et al. 2011; Emmrich et al. 2012; Stankov et al. 2014). Cell lines (CMK, K562, MV4:11, THP-1, and NB4) were purchased from the German National Resource Center for Biological Material (DSMZ) and maintained under recommended conditions. The ALK inhibitor SB43152 (SelleckChem), Indo (SelleckChem), BIO (Sigma), ICG-001 (SelleckChem), human recombinant TGF β 1 (Pepro- tech), and human Wnt3A (R&D Systems) were applied as indicated. All investigations were approved by the local ethics committee. Fluorescence microscopy was carried out with a BZ9000 (Keyence) microscope.

Mice

All studies involving mice were approved by the Hannover Medical School Institute for Laboratory Animal Science and local authorities and performed in accordance with the relevant protocol. BM from C57BL/6J mice was lineage-depleted using mouse hematopoietic progenitor cell enrichment kit (Stem Cell Technologies) and used for transduction. FL cells were depleted using biotinylated TER119 and Ly-6G/C antibodies (Stem Cell Technologies). Recipients were lethally irradiated (10 Gy) and transplanted with 3×10^5 transduced cells. CBC and WBC counts were obtained from the scil Vet ABC blood counter (Horiba Medical). Flow cytometry of total BM and PB was performed after red blood cell lysis (Pharm Lyse reagent, Becton Dickinson). For quantification of cells, stained samples were analyzed with TRUcount tubes (Becton Dickinson) according to the manufacturer's instructions. For secondary transplantation,

one-third of the whole BM of each mouse per construct was pooled and injected per lethally irradiated secondary recipient.

Constructs and lentivirus

Cloning of *miR-99a*, *let-7c*, and *miR-125b-2* (alone and in combination) as well as the *miR-100/let-7a-2/miR-125b-1* tricistron from genomic DNA into a modified LeGO vector was performed as previously described (Weber et al. 2008; Emmrich et al. 2012). A nonsilencing shMiR in the miR-30 backbone (Open Biosystems) or miR-E backbone (Fellmann et al. 2013) was subcloned to the LeGO construct and used as control (referred to as nonsilencing miRNA). shRNAs directed to human *HOXA10* were obtained from Open Biosystems (clone IDs: V2LHS_192251, and V2LHS_244712) and subcloned into the LeGO miR-30 backbone construct. shRNAs directed to human *APC* (ID: APC.3311) and *SMAD4* (ID: SMAD4.2580) were cloned into the miR-E backbone. For the superinfection experiments, we sorted single-positive (Venus- or mCherry-positive) and double-positive cells, resulting in either sh-APC-expressing, sh-SMAD4-expressing, or sh-APC/sh-SMAD4-expressing cells. Endogenous promoter activity assays in cell lines were performed with a TK-GFP lentiviral reporter construct (kind gift of Dr. Orkin's laboratory, Boston Children's Hospital), where the TK promoter was replaced by the putative promoter fragments. Stable miRNA knockdown was achieved using the sponge technology (Loya et al. 2009). Briefly, we inserted eight to 16 specific target sites of each miRNA as an artificial 3' UTR behind the sense SFV-driven mCherry cassette, while an antisense CMV-driven GFP-IRES-Puro served as selection marker (pLBid-GIP/C vector) (Supplemental Fig. S5C,D; Maetzig et al. 2010). The SP-sc control sequence was adapted from Loya et al. (2009). The MSCV:HoxA10 vector was obtained as a kind gift from Dr. Heuser (Hannover Medical School). For the HSPC studies, human *HOXA10* and *PBX1* were cloned in a modified LeGO vector with a cerulean or GFP expression cassette, respectively. Lentiviral supernatant was generated and collected using standard protocols and as described (Emmrich et al. 2012; Maroz et al. 2013).

Microarray data collection and analysis

Microarray expression profiles were collected using human GE 4x44K v2 chips for mRNA and human miRNA microarray release 14.0, 8x15K chips for miRNA expression (both Agilent) and analyzed using GeneSpringXII (Agilent) and GSEA (Subramanian et al. 2005). For miRNA target gene prediction, we used the miRecords database (Xiao et al. 2009). All microarray data have been deposited in NCBI's Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo>) with GEO series accession number GSE56335.

Statistics

Statistical evaluation between the two groups was carried out using Student's *t*-test and for more than two groups by one-way ANOVA with Tukey's or Sidak's post-hoc analysis. The level of significance was set at $P < 0.05$. All data are presented as mean $\pm$ SD or SEM, as indicated. Calculations were performed using GraphPad Prism 6.

Acknowledgments

We thank Dr. S.H. Orkin and Dr. S. Meyer for critically reading the manuscript and helpful discussions; M. Ballmaier for cell sorting; M. El-Khatib for help with experimental validation;

E. Pittermann, R. Jammal, R.-M. Struß, D. Heckl, and L. Queisser for technical assistance; and J. Zuber, K. Weber, and B. Fehse for providing plasmids. This work was supported by a grant to J.-H.K. from the German Research Foundation (DFG) within the Emmy Noether-Programme (KL-2374/2-1). S.E., M.R., S.K., and A.M. were supported by the Hannover Biomedical Research School. S.K. is supported by the DAAD. Z.L. was supported by the American Association for Cancer Research-Aflac, Incorporated Career Development Award for Pediatric Cancer Research (10-20-10-LI) and National Institutes of Health grant R01 HL107663.

References

- Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H. 2005. Clustering and conservation patterns of human microRNAs. *Nucleic Acids Res* **33**: 2697–2706.
- Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, et al. 2011. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell* **8**: 376–388.
- Bjornsson JM, Andersson E, Lundstrom P, Larsson N, Xu X, Repetowska E, Humphries RK, Karlsson S. 2001. Proliferation of primitive myeloid progenitors can be reversibly induced by *HOXA10*. *Blood* **98**: 3301–3308.
- Bobbs AS, Saarela AV, Yatskevych TA, Antin PB. 2012. Fibroblast growth factor (FGF) signaling during gastrulation negatively modulates the abundance of microRNAs that regulate proteins required for cell migration and embryo patterning. *J Biol Chem* **287**: 38505–38514.
- Boissart C, Nissan X, Giraud-Triboulet K, Peschanski M, Benchoua A. 2012. miR-125 potentiates early neural specification of human embryonic stem cells. *Development* **139**: 1247–1257.
- Bousquet M, Harris MH, Zhou B, Lodish HF. 2010. MicroRNA miR-125b causes leukemia. *Proc Natl Acad Sci* **107**: 21558–21563.
- Chan WC, Ho MR, Li SC, Tsai KW, Lai CH, Hsu CN, Lin WC. 2012. MetaMirClust: discovery of miRNA cluster patterns using a data-mining approach. *Genomics* **100**: 141–148.
- Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD, Rao DS, O'Connell RM, Baltimore D. 2012. Oncomir miR-125b regulates hematopoiesis by targeting the gene *Lin28A*. *Proc Natl Acad Sci* **109**: 4233–4238.
- Chen PS, Su JL, Cha ST, Tarn WY, Wang MY, Hsu HC, Lin MT, Chu CY, Hua KT, Chen CN, et al. 2011. miR-107 promotes tumor progression by targeting the *let-7* microRNA in mice and humans. *J Clin Invest* **121**: 3442–3455.
- Chen PY, Qin L, Barnes C, Charisse K, Yi T, Zhang X, Ali R, Medina PP, Yu J, Slack FJ, et al. 2012. FGF regulates TGF- β signaling and endothelial-to-mesenchymal transition via control of *let-7* miRNA expression. *Cell Rep* **2**: 1684–1696.
- Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, et al. 2012. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. *Blood* **120**: 3187–3205.
- Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. 1998. Direct binding of Smad3 and Smad4 to critical TGF- β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J* **17**: 3091–3100.
- Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, et al. 2004. A small

- molecule inhibitor of β -catenin/CREB-binding protein transcription [corrected]. *Proc Natl Acad Sci* **101**: 12682–12687.
- Emmrich S, Henke K, Hegermann J, Ochs M, Reinhardt D, Klusmann JH. 2012. miRNAs can increase the efficiency of ex vivo platelet generation. *Ann Hematol* **91**: 1673–1684.
- Emmrich S, Katsman-Kuipers JE, Henke K, Khatib ME, Jammal R, Engeland F, Dasci F, Zwaan CM, den Boer ML, Verboon L, et al. 2013. miR-9 is a tumor suppressor in pediatric AML with t(8;21). *Leukemia* doi: 10.1038/leu.2013.357.
- Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, et al. 2011. Emu/miR-125b transgenic mice develop lethal B-cell malignancies. *Leukemia* **25**: 1849–1856.
- Fava RA, Casey TT, Wilcox J, Pelton RW, Moses HL, Nanney LB. 1990. Synthesis of transforming growth factor- β 1 by megakaryocytes and its localization to megakaryocyte and platelet α -granules. *Blood* **76**: 1946–1955.
- Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y, et al. 2013. An optimized microRNA backbone for effective single-copy RNAi. *Cell Rep* **5**: 1704–1713.
- Fortunel N, Batard P, Hatzfeld A, Monier MN, Panterne B, Lebkowski J, Hatzfeld J. 1998. High proliferative potential-quiescent cells: a working model to study primitive quiescent hematopoietic cells. *J Cell Sci* **111**: 1867–1875.
- Fortunel NO, Hatzfeld A, Hatzfeld JA. 2000. Transforming growth factor- β : pleiotropic role in the regulation of hematopoiesis. *Blood* **96**: 2022–2036.
- Gerrits A, Walasek MA, Olthof S, Weersing E, Ritsema M, Zwart E, van Os R, Bystrykh LV, de Haan G. 2012. Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. *Blood* **119**: 377–387.
- Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, Moon RT, et al. 2009. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. *Cell* **136**: 1136–1147.
- Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, Purton LE, Fleming HH, Cobb B, Merckenschlager M, et al. 2010. MicroRNA miR-125a controls hematopoietic stem cell number. *Proc Natl Acad Sci* **107**: 14229–14234.
- Hagan JP, Piskounova E, Gregory RI. 2009. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. *Nat Struct Mol Biol* **16**: 1021–1025.
- Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA. 2002. Indomethacin induces differential expression of β -catenin, γ -catenin and T-cell factor target genes in human colorectal cancer cells. *Carcinogenesis* **23**: 107–114.
- He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al. 2005. A microRNA polycistron as a potential human oncogene. *Nature* **435**: 828–833.
- Jacobsen SE, Keller JR, Ruscetti FW, Kondaiah P, Roberts AB, Falk LA. 1991. Bidirectional effects of transforming growth factor β (TGF- β) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF- β isoforms. *Blood* **78**: 2239–2247.
- Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, Nimer SD. 2000. Inhibition of the transforming growth factor β 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. *J Biol Chem* **275**: 40282–40287.
- Jeanpierre S, Nicolini FE, Kaniewski B, Dumontet C, Rimokh R, Puisieux A, Maguer-Satta V. 2008. BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. *Blood* **112**: 3154–3163.
- Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 2005. RAS is regulated by the let-7 microRNA family. *Cell* **120**: 635–647.
- Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. 2006. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. *Nat Immunol* **7**: 1048–1056.
- Klaus A, Birchmeier W. 2008. Wnt signalling and its impact on development and cancer. *Nat Rev Cancer* **8**: 387–398.
- Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D, Orkin SH, Li Z. 2010a. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. *Genes Dev* **24**: 1659–1672.
- Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D. 2010b. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. *Genes Dev* **24**: 478–490.
- Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, et al. 2011. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q[−] syndrome. *Blood* **118**: 4666–4673.
- Lee YS, Dutta A. 2007. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. *Genes Dev* **21**: 1025–1030.
- Lee YT, de Vasconcellos JF, Yuan J, Byrnes C, Noh SJ, Meier ER, Kim KS, Rabel A, Kaushal M, Muljo SA, et al. 2013. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. *Blood* **122**: 1034–1041.
- Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol* **20**: 781–810.
- Loya CM, Lu CS, Van Vactor D, Fulga TA. 2009. Transgenic microRNA inhibition with spatiotemporal specificity in intact organisms. *Nat Methods* **6**: 897–903.
- Luis TC, Naber BA, Roozen PP, Brugman MH, de Haas EF, Ghazvini M, Fibbe WE, van Dongen JJ, Fodde R, Staal FJ. 2011. Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. *Cell Stem Cell* **9**: 345–356.
- Luis TC, Ichii M, Brugman MH, Kincade P, Staal FJ. 2012. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. *Leukemia* **26**: 414–421.
- Macaulay IC, Thon JN, Tijssen MR, Steele BM, MacDonald BT, Meade G, Burns P, Rendon A, Salunkhe V, Murphy RP, et al. 2013. Canonical Wnt signaling in megakaryocytes regulates proplatelet formation. *Blood* **121**: 188–196.
- Maetzig T, Galla M, Brugman MH, Loew R, Baum C, Schambach A. 2010. Mechanisms controlling titer and expression of bi-directional lentiviral and γ retroviral vectors. *Gene Ther* **17**: 400–411.
- Magnusson M, Brun AC, Miyake N, Larsson J, Ehinger M, Bjornsson JM, Wutz A, Sigvardsson M, Karlsson S. 2007. HOXA10 is a critical regulator for hematopoietic stem cells and erythroid/megakaryocyte development. *Blood* **109**: 3687–3696.
- Maguer-Satta V, Bartholin L, Jeanpierre S, Ffrench M, Martel S, Magaud JP, Rimokh R. 2003. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGF β family. *Exp Cell Res* **282**: 110–120.
- Maroz A, Stachorski L, Emmrich S, Reinhardt K, Xu J, Shao Z, Kabler S, Dertmann T, Hitzler J, Roberts I, et al. 2013. GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. *Leukemia* doi: 10.1038/leu.2013.373.

- Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J, et al. 2008. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. *Cell* **134**: 521–533.
- Massague J. 2008. TGF β in cancer. *Cell* **134**: 215–230.
- Moustakas A, Heldin CH. 2009. The regulation of TGF β signal transduction. *Development* **136**: 3699–3714.
- Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogradowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A. 2009. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. *Genes Dev* **23**: 2806–2811.
- O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. 2010. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. *Proc Natl Acad Sci* **107**: 14235–14240.
- Ooi AG, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY. 2010. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. *Proc Natl Acad Sci* **107**: 21505–21510.
- Oshimori N, Fuchs E. 2012. The harmonies played by TGF- β in stem cell biology. *Cell Stem Cell* **11**: 751–764.
- Ovcharenko I, Loots GG, Giardine BM, Hou M, Ma J, Hardison RC, Stubbs L, Miller W. 2005. Mulan: multiple-sequence local alignment and visualization for studying function and evolution. *Genome Res* **15**: 184–194.
- Parisi S, Battista M, Musto A, Navarra A, Tarantino C, Russo T. 2012. A regulatory loop involving *Dies1* and miR-125a controls BMP4 signaling in mouse embryonic stem cells. *FASEB J* **26**: 3957–3968.
- Pelosi A, Careccia S, Lulli V, Romania P, Marziali G, Testa U, Lavorgna S, Lo-Coco F, Petti MC, Calabretta B, et al. 2013. miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. *Oncogene* **32**: 3648–3654.
- Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, White A, Kent D, Marmolejo L, Heuser M, Berg T, Copley M, et al. 2010. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. *Proc Natl Acad Sci* **107**: 15443–15448.
- Pietras EM, Warr MR, Passegue E. 2011. Cell cycle regulation in hematopoietic stem cells. *J Cell Biol* **195**: 709–720.
- Rorby E, Hagerstrom MN, Blank U, Karlsson G, Karlsson S. 2012. Human hematopoietic stem/progenitor cells overexpressing *Smad4* exhibit impaired reconstitution potential in vivo. *Blood* **120**: 4343–4351.
- Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. 2012. miR-125 in normal and malignant hematopoiesis. *Leukemia* **26**: 2011–2018.
- Stankov MV, El Khatib M, Kumar TB, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, et al. 2014. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. *Leukemia* **28**: 577–588.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci* **102**: 15545–15550.
- Surdziel E, Cabanski M, Dallmann I, Lyszkiewicz M, Krueger A, Ganser A, Scherr M, Eder M. 2011. Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways. *Blood* **117**: 4338–4348.
- Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK. 1997. Overexpression of *HOXA10* in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. *Mol Cell Biol* **17**: 495–505.
- Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. 2010. The Wnt/ β -catenin pathway is required for the development of leukemia stem cells in AML. *Science* **327**: 1650–1653.
- Weber K, Bartsch U, Stocking C, Fehse B. 2008. A multicolor panel of novel lentiviral 'gene ontology' (LeGO) vectors for functional gene analysis. *Mol Ther* **16**: 698–706.
- Weber K, Thomaschewski M, Warlich M, Volz T, Cornils K, Niebuhr B, Tager M, Lutgehetmann M, Pollok JM, Stocking C, et al. 2011. RGB marking facilitates multicolor clonal cell tracking. *Nat Med* **17**: 504–509.
- Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. 2009. miRecords: an integrated resource for microRNA-target interactions. *Nucleic Acids Res* **37**: D105–D110.
- Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, Lin KY, Zhou H, Qu LH, Zhang P, et al. 2012. MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. *Oncogene* **31**: 80–92.

***miR-99a/100~125b* tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGF β and Wnt signaling**

Stephan Emmrich, Mareike Rasche, Jennifer Schöning, et al.

Genes Dev. 2014, **28**:

Access the most recent version at doi:[10.1101/gad.233791.113](https://doi.org/10.1101/gad.233791.113)

Supplemental Material <http://genesdev.cshlp.org/content/suppl/2014/04/15/28.8.858.DC1>

References This article cites 67 articles, 35 of which can be accessed free at:
<http://genesdev.cshlp.org/content/28/8/858.full.html#ref-list-1>

Creative Commons License This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genesdev.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Focused on your science.

USC
SCIENTIFIC
SIDE BY SCIENCE